This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Merrimack Does Well to License Marginal Cancer Drug to Baxter

09/24/14 - 08:14 AM EDT

Baxter has a hunger for cancer drugs with hair.

READ FULL POST

Tekmira Experimental Ebola Drug Used to Treat Stricken U.S. Doctor

09/22/14 - 07:48 PM EDT

Ebola patient Dr. Rick Sacra received treatment with Tekmira Pharmaceuticals' experimental ebola therapy TKM-Ebola for seven days, Nebraska Medical Center confirmed.

READ FULL POST

Northwest Bio's Almost-Toxic Debt Raise Responsible for Stock Slide

09/22/14 - 08:59 AM EDT

The buyers of Northwest's debt want the stock price to decline before Feb. 15, 2015, because a lower stock price also will drop the conversion price of the notes.

READ FULL POST

Ariad Director Resignation May Mean CEO Berger One Step Closer to Exit

09/19/14 - 12:05 PM EDT

Activist investor Alex Denner is gaining an ally on Ariad's Board.

READ FULL POST

SEC Slaps Biotech Hedge Fund for Short-Selling Violations

09/16/14 - 01:04 PM EDT

On 17 occasions, RA Capital bought shares in biotech company financings after having sold short shares of the same company when it was supposed to be restricted from doing so.

READ FULL POST

Avanir's Over-Priced Cough Syrup Touted for Role in Alzheimer's Agitation

09/15/14 - 10:19 AM EDT

Avanir Pharmaceuticals are surging Monday after demonstrating once again that cough syrup produces a nice, mellow high

READ FULL POST

Third Time Was No Charm, FDA Denies Amarin Vascepa SPA Appeal

09/12/14 - 09:43 AM EDT

Amarin evaluating next steps following FDA's decision to denial reinstatement of Vascepa SPA for 'Anchor" indication.

READ FULL POST

Orexigen's Obesity Pill is Approved and Stock Falls. Don't be Surprised

09/11/14 - 01:23 PM EDT

Orexigen's Contrave must prove it can top the dismal obesity pill launches of its competitors Arena and Vivus.

READ FULL POST

Medivation Prostate Cancer Drug Secures Expanded FDA Label

09/10/14 - 03:37 PM EDT

Language in the new Xtandi label should help Medivation and Astellas widen their market share lead over Johnson & Johnson's competing prostate cancer drug Zytiga.

READ FULL POST

J.P. Morgan Biotech Analyst Meacham Exits for New Barclays Gig

09/08/14 - 08:48 AM EDT

Meacham is taking a new job at Barclays where he will cover biotech and pharma stocks.

READ FULL POST

Adam Feuerstein is a senior columnist at TheStreet in charge of covering biotechnology and pharmaceutical stocks.

Feuerstein has been a financial journalist for more than 20 years. He joined TheStreet in 2001, leaving in 2005 for a two-year stint as a biotech analyst for a New York-based investment management firm. Feuerstein rejoined TheStreet in 2007. Prior to his work at TheStreet, Feuerstein wrote about Internet startups and business software for Upside.com. Covering the dot-com boom and bust of the 1990s and early 2000s made Feuerstein very cynical, a trait he applies to great effect by highlighting the often-overlooked risks of biotech stock investing. In what can only be considered a high compliment, a particularly promotional sell-side analyst once warned his clients that Feuerstein "attacks viciously".

Expand Bio +

Feuerstein lives near Boston with his wife, two kids and a yellow lab-golden retriever named Max. When Feuerstein is not writing article and blog posts for TheStreet, he's tweeting. In fact, when Feuerstein is working, he's tweeting. All the time. He also runs, bikes, watches a lot of English soccer matches (Go Spurs!) and loves to cook.

Close Bio -

Markets

DOW 17,730.11 -27.80 -0.16%
S&P 500 2,076.78 -0.64 -0.03%
NASDAQ 5,009.2140 -3.9090 -0.08%

Adam's Tweets

Top Rated Stocks Top Rated Funds Top Rated ETFs